(NASDAQ: BRTX) Biorestorative Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Biorestorative Therapies's earnings in 2025 is -$12,095,925.On average, 1 Wall Street analyst forecast BRTX's earnings for 2025 to be -$12,608,030, with the lowest BRTX earnings forecast at -$12,608,030, and the highest BRTX earnings forecast at -$12,608,030. On average, 1 Wall Street analyst forecast BRTX's earnings for 2026 to be -$9,756,214, with the lowest BRTX earnings forecast at -$9,756,214, and the highest BRTX earnings forecast at -$9,756,214.
In 2027, BRTX is forecast to generate $23,414,914 in earnings, with the lowest earnings forecast at $23,414,914 and the highest earnings forecast at $23,414,914.